Breaking Advances
Cancer Res January 15 2011 71 (2) 291-292;
Table of Contents
Breaking Advances
Reviews
- ReviewsDong Woo Kang, Kang-Yell Choi and Do Sik MinCancer Res January 15 2011 71 (2) 293-297; DOI:10.1158/0008-5472.CAN-10-2463
- ReviewsHermann B. Frieboes, Mark A.J. Chaplain, Alastair M. Thompson, Elaine L. Bearer, John S. Lowengrub and Vittorio CristiniCancer Res January 15 2011 71 (2) 298-302; DOI:10.1158/0008-5472.CAN-10-2676
Perspective
- PerspectiveSonya E.L. Craig and Susann M. Brady-KalnayCancer Res January 15 2011 71 (2) 303-309; DOI:10.1158/0008-5472.CAN-10-2301
Meeting Reports
- Meeting ReportsEvan T. Keller and Lu-Yuan LiCancer Res January 15 2011 71 (2) 310-313; DOI:10.1158/0008-5472.CAN-10-2930
- Meeting ReportsPushpa Tandon and Keyvan FarahaniCancer Res January 15 2011 71 (2) 314-317; DOI:10.1158/0008-5472.CAN-10-2629
Microenvironment and Immunology
- Microenvironment and ImmunologySanjib Banerjee, Chuen-Fu L. Lin, Kristin A. Skinner, Linda M. Schiffhauer, James Peacock, David G. Hicks, Eileen M. Redmond, David Morrow, Alissa Huston, Michelle Shayne, Howard N. Langstein, Carol L. Miller-Graziano, Jennifer Strickland, Lauren O'Donoghue and Asit K. DeCancer Res January 15 2011 71 (2) 318-327; DOI:10.1158/0008-5472.CAN-10-1778
Findings define a novel immune escape mechanism supporting breast cancer growth which is mediated by a heat shock chaperone protein.
- Microenvironment and ImmunologyAudrey Le Floc'h, Abdelali Jalil, Katarzyna Franciszkiewicz, Pierre Validire, Isabelle Vergnon and Fathia Mami-ChouaibCancer Res January 15 2011 71 (2) 328-338; DOI:10.1158/0008-5472.CAN-10-2457
This study defines a co-stimulatory signal for tumor-infiltrating T cells that is required along with T-cell receptor engagement to trigger cytolytic granule lysis of cancer cell targets.
Molecular and Cellular Pathobiology
- Molecular and Cellular PathobiologyNaoki Morito, Keigyou Yoh, Atsuko Maeda, Takako Nakano, Akiko Fujita, Manabu Kusakabe, Michito Hamada, Takashi Kudo, Kunihiro Yamagata and Satoru TakahashiCancer Res January 15 2011 71 (2) 339-348; DOI:10.1158/0008-5472.CAN-10-1057
A novel transgenic mouse model may offer an ideal system to study the pathogenesis of human multiple myeloma, an aggressive disease that remains relatively poorly managed.
- Molecular and Cellular PathobiologyJingjing Wu, Zhaojian Liu, Changshun Shao, Yaoqin Gong, Eva Hernando, Peng Lee, Masashi Narita, William Muller, Jinsong Liu and Jian-Jun WeiCancer Res January 15 2011 71 (2) 349-359; DOI:10.1158/0008-5472.CAN-10-2550
Introduction of HMGA2 overexpression in ovarian surface epithelial cells is sufficient for a tumor transformation both in vitro and in vivo through regulation of epithelial to mesenchymal transition.
- Molecular and Cellular PathobiologyHong-Gang Yu, Ju-Ock Nam, Nichol L. G. Miller, Isabelle Tanjoni, Colin Walsh, Lei Shi, Linda Kim, Xiao Lei Chen, Alok Tomar, Ssang-Taek Lim and David D. SchlaepferCancer Res January 15 2011 71 (2) 360-370; DOI:10.1158/0008-5472.CAN-10-2894
Findings reveal a mechanism through which the pro-tumorigenic gastrointestinal hormone gastrin acts to promote invadopodia formation and invasive motility of colorectal carcinoma cells.
- Molecular and Cellular PathobiologyYan Wang, Atsushi Ozawa, Shadia Zaman, Nijaguna B. Prasad, Settara C. Chandrasekharappa, Sunita K. Agarwal and Stephen J. MarxCancer Res January 15 2011 71 (2) 371-382; DOI:10.1158/0008-5472.CAN-10-3221
Restricting membrane translocation of AKT from the cytoplasm may have important implications for endocrine cancers and possibly other cancers where AKT dysregulation often occurs.
- Molecular and Cellular PathobiologyWen-Hsin Chang, Ta-Chih Liu, Wen-Kuang Yang, Chien-Chih Lee, Yi-Hsiung Lin, Tsai-Yun Chen and Jan-Gowth ChangCancer Res January 15 2011 71 (2) 383-392; DOI:10.1158/0008-5472.CAN-10-1037
Findings offer a mechanistic rationale based on modulation of alternate RNA splicing for testing of a common anti-hypertensive drug as an adjuvant therapy in leukemia.
- Molecular and Cellular PathobiologyFeng Zhu, Tatyana A. Zykova, Cong Peng, Jishuai Zhang, Yong-Yeon Cho, Duo Zheng, Ke Yao, Wei-Ya Ma, Andy T. Y. Lau, Ann M. Bode and Zigang DongCancer Res January 15 2011 71 (2) 393-403; DOI:10.1158/0008-5472.CAN-10-2012
Findings define a new function for histone H2AX, a marker of DNA damage response and repair, that may inform the role of its phosphorylation in oncogenesis.
- Molecular and Cellular PathobiologyNunzio Iraci, Daniel Diolaiti, Antonella Papa, Antonio Porro, Emanuele Valli, Samuele Gherardi, Steffi Herold, Martin Eilers, Roberto Bernardoni, Giuliano Della Valle and Giovanni PeriniCancer Res January 15 2011 71 (2) 404-412; DOI:10.1158/0008-5472.CAN-10-2627
Findings establish a key pathway of clinical pathogenicity and aggressiveness in neuroblastoma, suggesting the use of HDAC inhibitors and nerve growth factor to treat MYCN-amplified tumors with the poorest prognosis.
Prevention and Epidemiology
- Prevention and EpidemiologyThomas U. Ahearn, Marjorie L. McCullough, W. Dana Flanders, Qi Long, Eduard Sidelnikov, Veronika Fedirko, Carrie R. Daniel, Robin E. Rutherford, Aasma Shaukat and Roberd M. BostickCancer Res January 15 2011 71 (2) 413-423; DOI:10.1158/0008-5472.CAN-10-1560
Findings offer mechanstic evidence for calcium and vitamin D3 as chemopreventive agents against colorectal neoplasms, suggesting several modifiable, pre-neoplastic risk biomarkers for colorectal neoplasms.
Therapeutics, Targets, and Chemical Biology
- Therapeutics, Targets, and Chemical BiologyChi-Wen Lo, Min-Wei Chen, Michael Hsiao, Shiuan Wang, Chi-An Chen, Sheng-Mou Hsiao, Jeng-Shou Chang, Tsung-Ching Lai, Stefan Rose-John, Min-Liang Kuo and Lin-Hung WeiCancer Res January 15 2011 71 (2) 424-434; DOI:10.1158/0008-5472.CAN-10-1496
Pathogenic effects of soluble receptor IL-6Rα in ovarian cancer might be specifically antagonized to enhance chemotherapeutic efficacy in ovarian cancer.
- Therapeutics, Targets, and Chemical BiologyGerrit J. P. Dijkgraaf, Bruno Alicke, Lasse Weinmann, Thomas Januario, Kristina West, Zora Modrusan, Dan Burdick, Richard Goldsmith, Kirk Robarge, Dan Sutherlin, Suzie J. Scales, Stephen E. Gould, Robert L. Yauch and Frederic J. de SauvageCancer Res January 15 2011 71 (2) 435-444; DOI:10.1158/0008-5472.CAN-10-2876
Findings suggest tactics to circumvent acquired resistance to a Hedgehog pathway inhibitor that is currently in clinical development as an anticancer treatment.
- Therapeutics, Targets, and Chemical BiologyJuyong Yoon, Kyoung-Hwa Koo and Kang-Yell ChoiCancer Res January 15 2011 71 (2) 445-453; DOI:10.1158/0008-5472.CAN-10-3058
Findings describe a drug therapy that can attack tumors with K-ras mutations that are resistant to existing EGFR specific therapies.
- Therapeutics, Targets, and Chemical BiologySteven A. Belinsky, Marcie J. Grimes, Maria A. Picchi, Hugh D. Mitchell, Chris A. Stidley, Yohannes Tesfaigzi, Meghan M. Channell, Yanbin Liu, Robert A. Casero , Jr., Stephen B. Baylin, Mathew D. Reed, Carmen S. Tellez and Thomas H. MarchCancer Res January 15 2011 71 (2) 454-462; DOI:10.1158/0008-5472.CAN-10-3184
This study offers new insights into how epigenetic therapy may affect different tumor cell populations and impact cell differentiation through activation of polycomb marked genes and pathways implicated in development.
- Therapeutics, Targets, and Chemical BiologyVictoria E. Anderson, Michael I. Walton, Paul D. Eve, Katherine J. Boxall, Laurent Antoni, John J. Caldwell, Wynne Aherne, Laurence H. Pearl, Antony W. Oliver, Ian Collins and Michelle D. GarrettCancer Res January 15 2011 71 (2) 463-472; DOI:10.1158/0008-5472.CAN-10-1252
While encouraging the concept of combining CHK2 inhibition with genotxic anti-cancer drugs, this study also strongly supports the use of CHK2 inhibitors to potentiate the anticancer effects of PARP inhibitors, an exciting new modality for cancer treatment.
- Therapeutics, Targets, and Chemical BiologyJia-Yang Chen, Yen-An Tang, Sin-Ming Huang, Hsueh-Fen Juan, Li-Wha Wu, Ying-Chieh Sun, Szu-Chi Wang, Kuan-Wei Wu, Gopula Balraj, Tzu-Ting Chang, Wen-Shan Li, Hung-Chi Cheng and Yi-Ching WangCancer Res January 15 2011 71 (2) 473-483; DOI:10.1158/0008-5472.CAN-10-1303
Findings offer preclinical proof-of-concept that small molecule inhibitors of a glycoprotein modifying enzyme could offer a widely applicable strategy to treat advanced cancers.
- Therapeutics, Targets, and Chemical BiologyAnne-Laure Rérole, Jessica Gobbo, Aurelie De Thonel, Elise Schmitt, Jean Paul Pais de Barros, Arlette Hammann, David Lanneau, Eric Fourmaux, Oleg Deminov, Olivier Micheau, Laurent Lagrost, Pierre Colas, Guido Kroemer and Carmen GarridoCancer Res January 15 2011 71 (2) 484-495; DOI:10.1158/0008-5472.CAN-10-1443
Lead compounds offer proof- of- concept for aptamer peptides that can exert immunogenic anti-tumor effects based on blockade of the central protein-folding chaperone molecule Hsp70.
- Therapeutics, Targets, and Chemical BiologyMurray J. Towle, Kathleen A. Salvato, Bruce F. Wels, Kimberley K. Aalfs, Wanjun Zheng, Boris M. Seletsky, Xiaojie Zhu, Bryan M. Lewis, Yoshito Kishi, Melvin J. Yu and Bruce A. LittlefieldCancer Res January 15 2011 71 (2) 496-505; DOI:10.1158/0008-5472.CAN-10-1874
A mechanistically unique microtubule inhibitor in Phase III trials induces an irreversible mitotic block that contributes to its in vivo antitumor efficacy under intermittent dosing conditions.
- Therapeutics, Targets, and Chemical BiologyJin H. Song, Karthikeyan Kandasamy, Marina Zemskova, Ying-Wei Lin and Andrew S. KraftCancer Res January 15 2011 71 (2) 506-515; DOI:10.1158/0008-5472.CAN-10-1977
An important pro-apoptotic drug currently in human clinical trials is found to activate gene transcription, heighten DNA damage, and trigger senescence in cancer cells that are not susceptible to death induced by this agent, potentially expanding its effective use as a cancer therapy.
- Therapeutics, Targets, and Chemical BiologyThorsten Klamp, Jens Schumacher, Georg Huber, Christoph Kühne, Ulrich Meissner, Abderraouf Selmi, Thomas Hiller, Sebastian Kreiter, Jürgen Markl, Özlem Türeci and Ugur SahinCancer Res January 15 2011 71 (2) 516-527; DOI:10.1158/0008-5472.CAN-10-2292
Findings describe a novel, chimeric bio-nanoparticle based vaccine that induces auto-antibodies directed against the native conformation of a pan-cancer target and demonstrating cytocidal and tumoricidal effector functions.
- Therapeutics, Targets, and Chemical BiologyDaniel E. Frigo, Matthew K. Howe, Bryan M. Wittmann, Abigail M. Brunner, Ian Cushman, Qianben Wang, Myles Brown, Anthony R. Means and Donald P. McDonnellCancer Res January 15 2011 71 (2) 528-537; DOI:10.1158/0008-5472.CAN-10-2581
This study describes a pathogenic growth regulatory pathway in prostate cancer that suggests important novel targets for therapy.
- Therapeutics, Targets, and Chemical BiologySahdeo Prasad, Vivek R. Yadav, Jayaraj Ravindran and Bharat B. AggarwalCancer Res January 15 2011 71 (2) 538-549; DOI:10.1158/0008-5472.CAN-10-3121
Drugs that can defeat resistance mechanisms to TRAIL may improve opportunities to exploit the anti-cancer properties of this cytokine.
Tumor and Stem Cell Biology
- Tumor and Stem Cell BiologyFelix Moltzahn, Adam B. Olshen, Lauren Baehner, Andrew Peek, Lawrence Fong, Hubert Stöppler, Jeffry Simko, Joan F. Hilton, Peter Carroll and Robert BlellochCancer Res January 15 2011 71 (2) 550-560; DOI:10.1158/0008-5472.CAN-10-1229
MicroRNA signatures that can be detected in blood serum may allow definition of different risk-stratified patients with prostate cancer.
- Tumor and Stem Cell BiologyBeatriz Russell, Saumitri Bhattacharyya, Jeremy Keirsey, April Sandy, Patrick Grierson, Erin Perchiniak, Juraj Kavecansky, Samir Acharya and Joanna GrodenCancer Res January 15 2011 71 (2) 561-571; DOI:10.1158/0008-5472.CAN-10-1727
Results elucidate a DNA repair mechanism that is critical to maintain chromosome stability in cells, a deficiency which greatly increases cancer risk.
- Tumor and Stem Cell BiologyMyles C. Hodgson, Long-jiang Shao, Anna Frolov, Rile Li, Leif E. Peterson, Gustavo Ayala, Michael M. Ittmann, Nancy L. Weigel and Irina U. AgoulnikCancer Res January 15 2011 71 (2) 572-582; DOI:10.1158/0008-5472.CAN-10-2314
Findings strongly reinforce the concept that therapeutics which target Akt signaling are likely to be effective in blocking the growth of metastatic prostate cancer cells.
- Tumor and Stem Cell BiologyStephanie Ma, Yuen Piu Chan, Pak Shing Kwan, Terence K. Lee, Mingxia Yan, Kwan Ho Tang, Ming Tat Ling, Juergen R. Vielkind, Xin-Yuan Guan and Kwok Wah ChanCancer Res January 15 2011 71 (2) 583-592; DOI:10.1158/0008-5472.CAN-10-2587
Findings reveal an interesting microRNA-regulated extracellular tumor suppressor pathway that is critical to support androgen-independent prostate cancers and amenable to therapeutic disruption.
- Tumor and Stem Cell BiologyKoji Aoki, Fumihiko Kakizaki, Hiromi Sakashita, Toshiaki Manabe, Masahiro Aoki and Makoto M. TaketoCancer Res January 15 2011 71 (2) 593-602; DOI:10.1158/0008-5472.CAN-10-2842
A novel non-transcriptional function of CDX2 plays a key role in tumor suppression through stabilization of p27Kip1.
- Tumor and Stem Cell BiologyLyndsay V. Rhodes, Sarah P. Short, Nicole F. Neel, Virgilio A. Salvo, Yun Zhu, Steven Elliott, Yongkun Wei, Dihua Yu, Menghong Sun, Shannon E. Muir, Juan P. Fonseca, Melyssa R. Bratton, Chris Segar, Syreeta L. Tilghman, Tammy Sobolik-Delmaire, Linda W. Horton, Snjezana Zaja-Milatovic, Bridgette M. Collins-Burow, Scott Wadsworth, Barbara S. Beckman, Charles E. Wood, Suzanne A. Fuqua, Kenneth P. Nephew, Paul Dent, Rebecca A. Worthylake, Tyler J. Curiel, Mien-Chie Hung, Ann Richmond and Matthew E. BurowCancer Res January 15 2011 71 (2) 603-613; DOI:10.1158/0008-5472.CAN-10-3185
Findings describe a potentially important mechanism of resistance to endocrine therapies used widely in nearly all ER+ breast cancer patients, with implications on how to bypass this resistance mechanism.
- Tumor and Stem Cell Biology | Free ArticleSuling Liu, Christophe Ginestier, Sing J. Ou, Shawn G. Clouthier, Shivani H. Patel, Florence Monville, Hasan Korkaya, Amber Heath, Julie Dutcher, Celina G. Kleer, Younghun Jung, Gabriela Dontu, Russell Taichman and Max S. WichaCancer Res January 15 2011 71 (2) 614-624; DOI:10.1158/0008-5472.CAN-10-0538
Strategies aimed at interfering with the proposed cytokine loops may provide a means of targeting the cancer stem cell population.
Letter to the Editor
- Letter to the EditorKenneth R. HessCancer Res January 15 2011 71 (2) 625-625; DOI:10.1158/0008-5472.CAN-10-3296
Correction
- CorrectionCancer Res January 15 2011 71 (2) 626-626; DOI:10.1158/0008-5472.CAN-10-4187
January 2011
Volume 71, Issue 2
Volume 71, Issue 2
Issue Highlights
Jump to
Advertisement
